CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory lymphoma, however not all tumors respond...
Phase 1
Cleveland, Ohio, United States and 1 other location
patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a possible treatment option.ARV-3...
Phase 1
Cleveland, Ohio, United States and 13 other locations
TrAVeRse is a multicentre, open-label, Phase II study of AVR in treatment naïve MCL participants. The primary objective will be to assess the rate of...
Phase 2
Cleveland, Ohio, United States and 28 other locations
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin,...
Phase 1
Cleveland, Ohio, United States and 27 other locations
This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/...
Phase 2
Cleveland, Ohio, United States and 55 other locations
The purpose of this trial is to measure the following in participants with relapsed and/or refractory B-cell lymphoma who receive epcoritama...
Phase 1, Phase 2
Cleveland, Ohio, United States and 84 other locations
(firi-cel), a CD22-directed autologous Chimeric Antigen Receptor (CAR) T-cell therapy for the treatment of relapsed or refractory large B-cell lymphoma...
Phase 2
Cleveland, Ohio, United States and 30 other locations
plus venetoclax (AV) versus venetoclax plus obinutuzumab (VO) in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma...
Phase 3
Cleveland, Ohio, United States and 40 other locations
ciloleucel, or lisocabtagene maraleucel) for diffuse large B-cell lymphoma that has come back (recurrent) or that does not respond to treatm...
Phase 2
Cleveland, Ohio, United States and 63 other locations
A multicenter, open-label Phase 2b study of selinexor (KPT-330) in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma...
Phase 2
Cleveland, Ohio, United States and 175 other locations
Clinical trials
Research sites
Resources
Legal